Nowhere is this issue more acute than in the United States. Despite leading in cancer care and innovation, cancer remains the second biggest killer. But without effective antibiotics, even the best treatments won’t be enough patients surviving cancer could succumb to untreatable infections.
The disparity in investment is stark:
đź’° Oncology investment surged by 900% to $7 billion, with cancer drug trials at record highs.
⚠️ Antibiotic R&D, meanwhile, remains critically underfunded—just $160 million was raised in 2020.
To fight cancer without also addressing drug resistance is not just a false economy but a major public health failure. If we are serious about tackling cancer, we must prioritize antibiotic development alongside new cancer treatments.